• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

    5/27/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Setting new standards for intelligent mass detection, sensitivity, and sustainability

    Agilent Technologies Inc. (NYSE:A) today announced the launch of its latest innovation in liquid chromatography (LC)-mass detection: the Agilent InfinityLab Pro iQ Series. This groundbreaking series includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, each tailored with distinct features and capabilities to meet the diverse analytical needs of modern laboratories. These advanced, intelligent systems are particularly well-suited for analyzing essential molecules such as therapeutic small molecules, oligonucleotides, peptides, and proteins.

    The Pro iQ Series is designed to serve a broad range of end markets, including pharmaceutical and biopharmaceutical industries, academic and government research institutions, environmental testing labs, food safety organizations, and the chemical and specialty materials sector. With its precision, sensitivity, and intelligent design, the series supports applications such as mass confirmation, impurity profiling, biomolecule characterization, trace contaminant detection, and compound purification—empowering scientists to achieve high-quality, reliable results in both routine and advanced analytical workflows.

    Dr. Iris Mangelschots, vice president and general manager of Agilent's Liquid Phase Division, emphasized the strategic significance of the launch:

    "With the launch of the Pro iQ Series, Agilent is redefining the future of liquid chromatography detection and demonstrating our continuing commitment to delivering leading-edge solutions to help customers push the boundaries of scientific discovery. The advanced Pro iQ Series will empower researchers to achieve unprecedented levels of insight and efficiency, making complex analyses more accessible and sustainable."

    The Pro iQ Series delivers exceptional performance and sensitivity, making it ideal for monitoring complex biomolecules and detecting impurities. Whether analyzing therapeutic small molecules, oligonucleotides, peptides, or proteins, the systems provide robust, high-resolution data to ensure accuracy, safety, and stability. The series also enables mass-based purification, allowing precise isolation of target compounds for downstream applications.

    The Pro iQ Plus system is engineered for high-end applications that demand ultimate sensitivity and performance. With an expanded mass range of m/z 2–3,000 and enhanced sensitivity through Agilent Jet Stream (AJS) technology, it supports both routine and trace-level detection of small and large molecules. These capabilities make it especially valuable in advanced R&D environments where extended analytical performance is critical.

    Both the Pro iQ and Pro iQ Plus systems are designed for operational efficiency and ease of use, enabling faster compound confirmation with greater specificity and selectivity than traditional UV detection—even for chromatographically unresolved compounds. The Pro iQ system, with a mass range of m/z 2–1,600, is optimized for small molecule analysis, making it a reliable choice for standard laboratory workflows.

    Jennifer Gushue, associate vice president of LC/MS Product Marketing at Agilent, highlighted the broad applicability of the new systems:

    "The versatility of the Pro iQ Series opens new possibilities across a wide spectrum of application areas—from pharmaceutical development and quality control to biotherapeutics, environmental testing, and academic research. Whether it's ensuring the purity of life-saving drugs, characterizing complex biomolecules—such as oligonucleotides and peptides—or advancing cutting-edge research, these systems deliver the precision, sensitivity, and intelligence today's scientists need to solve tomorrow's challenges."

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250527486106/en/

    Media Contact

    Naomi Goumillout

    Agilent Technologies

    +1.978.314.1862

    [email protected]

    Get the next $A alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agilent to Showcase New Products and Innovations at HPLC 2025

      Agilent Technologies Inc. (NYSE:A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical outcomes. The Agilent InfinityLab Pro iQ Series, launched at ASMS 2025, represents the next generation of LC-mass detection. With innovative hardware advancements, the series delivers enhanced sensitivity and analytical performance for oligonucleotides, therapeutic

      6/12/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Smackover Lithium's South West Arkansas Project Receives Royalty Rate Approval From the Arkansas Oil and Gas Commission

      LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of

      5/29/25 8:30:27 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials